A Phase 4 interventional study of Perforomist-Placebo and Perforomist, nebulization, COPD in COPD, sponsored by Dey. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-06-12.
Sponsored by Dey (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 17th largest by enrollment, is one of 3 that started in 2012, is one of 26 in phase 4, and was the 42nd registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 40+
By country, each count listing its studies:
formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,071 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 120 across the 89 interventional studies. Of the 80 that completed or were terminated, 38 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 89 have an industry lead sponsor. The 10 most frequent:
This study is registered under Dey, one of the names counted as Viatris Inc.. Under that name alone:
Dey is the lead sponsor of 21 studies on the registry; none are open to participants now.
26 studies in Pulmonary Disease, Chronic Obstructive by Viatris Inc.: none open now, none under way, none of them phase 3. Of 26 finished, 11 (42%) have results posted.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Viatris Inc., this one has the largest enrollment, is one of 2 that started in 2012, is the only one in phase 4, and was the 13th registered.
Viatris Inc.’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2005.
1 of the studies testing formoterol in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 26 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a multi-center, randomized, placebo-controlled study to evaluate the long-term safety of Perforomist® inhalation therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD). Individual participation is approximately 54 weeks, including 52 weeks of double-blind treatment.
None provided.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A history of to study drugs or their components, including albuterol rescue.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active
Drug: Perforomist, nebulization, COPD
Placebo
Drug: Perforomist-Placebo
Placebo vehicle, 2mL, twice daily for 52 weeks
Also known as: Perforomist
Perforomist, 20 mcg/2 mL, twice daily for 52 weeks
Also known as: Formoterol fumarate
Number of Subjects With a Primary Event of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation
The primary endpoint was the combined incidence of respiratory death, first COPD-related ER visit or first COPD exacerbation-related hospitalization (whichever occurred first from the time of randomization to the end of the study). The time-to-first event was measured and analyzed in units of weeks and was summarized by treatment for subjects in the Safety Set. An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.
Time frame: 0 to 52 weeks
Kaplan-Meier Probability of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation at 52 Weeks
The primary endpoint was the combined incidence of respiratory death, first COPD-related ER visit or first COPD exacerbation-related hospitalization (whichever occurred first from the time of randomization to the end of the study). The time-to-first event was measured and analyzed in units of weeks and was summarized by treatment for subjects in the Safety Set. An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.
Time frame: 0 to 52 weeks
Summary of All Cause Mortality, COPD Related Mortality and Respiratory Related Mortality
An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.
Time frame: 0 to 52 weeks
Individual Components of the Primary Composite Endpoint - First COPD-related ER Visit and First COPD Exacerbation-Related Hospitalization
Time frame: 0 to 52 weeks
Number of Subjects With Protocol-Defined COPD Exacerbation
COPD exacerbations were defined as events in the natural course of disease characterized by an increase from baseline in two of the following symptoms: dyspnea, cough, and sputum production that was beyond normal day-to-day variations, was acute in onset, that persisted for at least two consecutive days, and that warranted a change in their regular medication. The change could be either the initiation of additional treatment(s) or the intensification of a treatment the subject was already receiving, and the change must have been specifically to address the exacerbation event. COPD exacerbations occurring after the time of withdrawal or completion of the study were not included.
Time frame: 0 to 52 weeks
Kaplan-Meier Probability of Protocol Defined COPD Exacerbation at 52 Weeks
COPD exacerbations were defined as events in the natural course of disease characterized by an increase from baseline in two of the following symptoms: dyspnea, cough, and sputum production that was beyond normal day-to-day variations, was acute in onset, that persisted for at least two consecutive days, and that warranted a change in their regular medication.The change could be either the initiation of additional treatment(s) or the intensification of a treatment the subject was already receiving, and the change must have been specifically to address the exacerbation event. COPD exacerbations occurring after the time of withdrawal or completion of the study were not included.
Time frame: 0 to 52 weeks
FEV1 Changes From Baseline at Months 3, 6, 9 and 12
Time frame: On treatment at months 3, 6, 9 and 12
FVC Changes From Baseline at Months 3, 6, 9 and 12
Time frame: On treatment at months 3, 6, 9 and 12
IC Changes From Baseline at Months 3, 6, 9 and 12
Time frame: On treatment at months 3, 6, 9 and 12
Saint Georges Respiratory Questionnaire Scores: Changes From Baseline at Months 3, 6, 9, 12
Saint Georges Respiratory Questionnaire comprises 50 items in 3 sections, Symptoms, Activity, Impact, measuring health status in chronic airflow limitation. Symptoms captures level of symptomatology. Activity and Impact responses are either "yes" or "no". Scoring is from 0 to 100; 0 = no life quality impairment. A summary score for all items is calculated and ranges from 0 to 100, where 0 indicates best possible health status, 100 represents worst possible health status. Scores are calculated using weights attached to each item in the questionnaire - 4 unit changes are clinically meaningful.
Time frame: On treatment at months 3, 6, 9 and 12
Transition Dyspnea Index
The Transition Dyspnea Index (TDI) measures changes in dyspnea severity from the baseline as established by the BDI. It has 3 components: change in functional impairment, change in magnitude of task, and change in magnitude of effort, and each component is rated on a scale ranging from -3 (major deterioration) to +3 (major improvement). The 3 components are summed to provide a total score ranging from -9 to +9. The lower the score, the more deterioration in severity of dyspnea.
Time frame: On treatment at months 3, 6, 9 and 12
Health Care Utilization and Economic Impact - Number of Emergency Department Visits
Time frame: 0 to 52 weeks
Summary of Subjects Requiring Intubation or Non-Invasive Ventilation
Time frame: 0 to 52 weeks
Rescue Medication Usage
Number of puffs of rescue medication (albuterol pMDI) used per day
Time frame: 0 to 52 weeks
| Milestone | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| Started | 541 | 530 |
| Completed | 294 | 226 |
| Not completed | 247 | 304 |
The primary endpoint was the combined incidence of respiratory death, first COPD-related ER visit or first COPD exacerbation-related hospitalization (whichever occurred first from the time of randomization to the end of the study). The time-to-first event was measured and analyzed in units of weeks and was summarized by treatment for subjects in the Safety Set. An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.
| Participants | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| Number of Subjects With a Primary Event of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation | 64 | 57 |
The primary endpoint was the combined incidence of respiratory death, first COPD-related ER visit or first COPD exacerbation-related hospitalization (whichever occurred first from the time of randomization to the end of the study). The time-to-first event was measured and analyzed in units of weeks and was summarized by treatment for subjects in the Safety Set. An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.
| percent | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| Kaplan-Meier Probability of Respiratory Death, First COPD-Related Emergency Room Visit, or First COPD Exacerbation-Related Hospitalisation at 52 Weeks | 15.5 | 14.9 |
An independent Mortality Adjudication Board was used to evaluate all deaths that occurred in the study and for assigning cause of death and COPD-relatedness.
| Participants | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| Incidence of All Cause Mortalities | 3 | 10 |
| Incidence of Respiratory Related Mortalities | 0 | 1 |
| Incidence of COPD Related Mortalities | 0 | 1 |
| Participants | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| Subjects with a COPD- related ER Visit | 46 | 47 |
| Subjects with a COPD-Related Hospitalization | 39 | 43 |
COPD exacerbations were defined as events in the natural course of disease characterized by an increase from baseline in two of the following symptoms: dyspnea, cough, and sputum production that was beyond normal day-to-day variations, was acute in onset, that persisted for at least two consecutive days, and that warranted a change in their regular medication. The change could be either the initiation of additional treatment(s) or the intensification of a treatment the subject was already receiving, and the change must have been specifically to address the exacerbation event. COPD exacerbations occurring after the time of withdrawal or completion of the study were not included.
| Participants | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| Number of Subjects With Protocol-Defined COPD Exacerbation | 142 | 135 |
COPD exacerbations were defined as events in the natural course of disease characterized by an increase from baseline in two of the following symptoms: dyspnea, cough, and sputum production that was beyond normal day-to-day variations, was acute in onset, that persisted for at least two consecutive days, and that warranted a change in their regular medication.The change could be either the initiation of additional treatment(s) or the intensification of a treatment the subject was already receiving, and the change must have been specifically to address the exacerbation event. COPD exacerbations occurring after the time of withdrawal or completion of the study were not included.
| percent | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| Kaplan-Meier Probability of Protocol Defined COPD Exacerbation at 52 Weeks | 34.7 | 34.0 |
| Litres | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| Change from Baseline FEV1: Month 3 | 0.058 ± 0.0116 | 0.016 ± 0.0123 |
| Change from Baseline FEV1: Month 6 | 0.057 ± 0.0130 | 0.017 ± 0.0143 |
| Change from Baseline FEV1: Month 9 | 0.050 ± 0.0136 | 0.029 ± 0.0151 |
| Change from Baseline FEV1: Month 12 | 0.030 ± 0.0144 | 0.000 ± 0.0160 |
| Litres | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| Change from Baseline FVC: Month 3 | 0.1051 ± 0.40479 | 0.0062 ± 0.38724 |
| Change from Baseline FVC: Month 6 | 0.1006 ± 0.38875 | -0.0241 ± 0.37124 |
| Change from Baseline FVC: Month 9 | 0.1009 ± 0.39533 | -0.0254 ± 0.40947 |
| Change from Baseline FVC: Month 12 | 0.0645 ± 0.43490 | -0.0581 ± 0.38069 |
| Litres | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| Change from Baseline IC: Month 3 | 0.0287 ± 0.42478 | -0.0119 ± 0.39505 |
| Change from Baseline IC: Month 6 | 0.0440 ± 0.44862 | -0.0106 ± 0.43483 |
| Change from Baseline IC: Month 9 | 0.1584 ± 1.84290 | -0.0118 ± 0.43513 |
| Change from Baseline IC: Month 12 | 0.0477 ± 0.48057 | -0.0105 ± 0.44289 |
Saint Georges Respiratory Questionnaire comprises 50 items in 3 sections, Symptoms, Activity, Impact, measuring health status in chronic airflow limitation. Symptoms captures level of symptomatology. Activity and Impact responses are either "yes" or "no". Scoring is from 0 to 100; 0 = no life quality impairment. A summary score for all items is calculated and ranges from 0 to 100, where 0 indicates best possible health status, 100 represents worst possible health status. Scores are calculated using weights attached to each item in the questionnaire - 4 unit changes are clinically meaningful.
| units on a scale | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| Change from Baseline SGRQ Total Score: Month 3 | -3.252 ± 0.5472 | -2.027 ± 0.5727 |
| Change from Baseline SGRQ Total Score: Month 6 | -2.329 ± 0.6541 | -2.511 ± 0.7156 |
| Change from Baseline SGRQ Total Score: Month 9 | -2.021 ± 0.7022 | -2.115 ± 0.7681 |
| Change from Baseline SGRQ Total Score: Month 12 | -1.453 ± 0.7559 | -1.475 ± 0.8345 |
The Transition Dyspnea Index (TDI) measures changes in dyspnea severity from the baseline as established by the BDI. It has 3 components: change in functional impairment, change in magnitude of task, and change in magnitude of effort, and each component is rated on a scale ranging from -3 (major deterioration) to +3 (major improvement). The 3 components are summed to provide a total score ranging from -9 to +9. The lower the score, the more deterioration in severity of dyspnea.
| units on a scale | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| Month 3 | 0.7 ± 0.11 | 0.0 ± 0.12 |
| Month 6 | 0.5 ± 0.13 | 0.4 ± 0.14 |
| Month 9 | 0.7 ± 0.14 | 0.4 ± 0.15 |
| Month 12 | 0.5 ± 0.14 | 0.6 ± 0.16 |
| Participants | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| 0 | 447 | 437 |
| 1 | 78 | 75 |
| 2 | 15 | 16 |
| >=3 | 1 | 2 |
| Participants | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| Summary of Subjects Requiring Intubation or Non-Invasive Ventilation | 3 | 10 |
Number of puffs of rescue medication (albuterol pMDI) used per day
| Mean Puffs per Day | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| Baseline | 2.55 ± 2.496 | 2.52 ± 2.484 |
| Treatment Phase | 1.92 ± 2.063 | 2.35 ± 2.521 |
Collected over Approximately 14 months (date of signature of the Informed Consent Form to 30 days after last dose of study drug). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Perforomist Inhalation Solution | 3/541 (0.6%) | 86/541 (15.9%) | 374/541 (69.1%) |
| Matching Placebo | 10/530 (1.9%) | 85/530 (16%) | 369/530 (69.6%) |
| Event | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| COPDRespiratory, thoracic and mediastinal disorders | 39/541 | 40/530 |
| PneumoniaInfections and infestations | 10/541 | 10/530 |
| Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders | 6/541 | 6/530 |
| Acute Myocardial InfarctionCardiac disorders | 2/541 | 6/530 |
| Lobar PneumoniaInfections and infestations | 2/541 | 6/530 |
| SepsisInfections and infestations | 2/541 | 4/530 |
| Renal failure acuteRenal and urinary disorders | 1/541 | 4/530 |
| Coronary artery diseaseCardiac disorders | 3/541 | 3/530 |
| Cardiac arrestCardiac disorders | 1/541 | 3/530 |
| Cardiac failure congestiveCardiac disorders | 1/541 | 3/530 |
| Event | Perforomist Inhalation Solution | Matching Placebo |
|---|---|---|
| COPDRespiratory, thoracic and mediastinal disorders | 164/541 | 145/530 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 35/541 | 40/530 |
| CoughRespiratory, thoracic and mediastinal disorders | 39/541 | 24/530 |
| Upper Respiratory Tract InfectionInfections and infestations | 36/541 | 32/530 |
| BronchitisInfections and infestations | 34/541 | 26/530 |
| SinusitisInfections and infestations | 25/541 | 12/530 |
| NasopharyngitisInfections and infestations | 24/541 | 18/530 |
| HeadacheNervous system disorders | 21/541 | 22/530 |
| PneumoniaInfections and infestations | 18/541 | 18/530 |
| NauseaGastrointestinal disorders | 18/541 | 7/530 |
Safety Set
| Age, Continuous(years) | Perforomist Inhalation Solution | Matching Placebo | Total |
|---|---|---|---|
| Mean | 62.7 ± 9.01 | 62.5 ± 9.17 | 62.6 ± 9.09 |
| Sex: Female, Male(Participants) | Perforomist Inhalation Solution | Matching Placebo | Total |
|---|---|---|---|
| Female | 285 | 267 | 552 |
| Male | 256 | 263 | 519 |
| Ethnicity (NIH/OMB)(Participants) | Perforomist Inhalation Solution | Matching Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 29 | 26 | 55 |
| Not Hispanic or Latino | 512 | 504 | 1016 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Perforomist Inhalation Solution | Matching Placebo | Total |
|---|---|---|---|
| White | 483 | 478 | 961 |
| Black or African American | 51 | 46 | 97 |
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian or Pacific Islander | 4 | 1 | 5 |
| Other | 3 | 3 | 6 |
| Region of Enrollment(Participants) | Perforomist Inhalation Solution | Matching Placebo | Total |
|---|---|---|---|
| United States | 541 | 530 | 1071 |
| Screening COPD Severity (GOLD) n (%)(Participants) | Perforomist Inhalation Solution | Matching Placebo | Total |
|---|---|---|---|
| Moderate (% Predicted FEV1 50 to <80%) | 274 | 273 | 547 |
| Severe (% Predicted FEV1 30 to <50%) | 261 | 250 | 511 |
| Very Severe (% Predicted FEV1 <30%) | 3 | 4 | 7 |
| Not Reported/Unknown | 3 | 3 | 6 |
| Baseline FEV1(Litres) | Perforomist Inhalation Solution | Matching Placebo | Total |
|---|---|---|---|
| Mean | 1.2494 ± 0.47593 | 1.2926 ± 0.50496 | 1.2707 ± 0.49073 |
| Baseline % Predicted FEV1(%) | Perforomist Inhalation Solution | Matching Placebo | Total |
|---|---|---|---|
| Mean | 43.82 ± 12.646 | 44.89 ± 13.787 | 44.35 ± 13.226 |
7 further baseline measures are reported on the registry.
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Mar 2012, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Formoterol
Pulmonary Disease, Chronic Obstructive →